Axillary Node Management in Breast Cancer

Primary Recommendations

• The National Comprehensive Cancer Network recommends sentinel lymph node biopsy (SLNB) as the standard of care for axillary staging in clinically node-negative early-stage breast cancer, as it provides equivalent staging accuracy to axillary lymph node dissection (ALND) while significantly reducing morbidity, including lymphedema, pain, and sensory loss 1, 2

Clinical Algorithm for Axillary Management

• Patients with clinical Stage I or II breast cancer require pathologic assessment of axillary lymph node status, which should be confirmed by physical examination or negative core or fine needle aspiration (FNA) biopsy before proceeding with SLNB 1, 3, 4
• The American College of Surgeons recommends that SLNB requires an experienced sentinel lymph node team, and patients without access to experienced teams should be referred to centers with expertise 1, 4

Pathologic Assessment and Management

• The National Comprehensive Cancer Network recommends using H&E staining alone for treatment decisions and not routinely performing cytokeratin immunohistochemistry, as it does not improve overall survival at 5 years 1, 5
• If the SLN is negative, no further axillary surgery is required, and patients can proceed with appropriate breast surgery and systemic therapy based on tumor characteristics 1, 2
• For patients with micrometastases (0.2-2.0 mm) in treatment-naïve patients, no completion ALND is required, as micrometastases are prognostically equivalent to N0 disease 2
• The American College of Surgeons recommends that for patients with T1/T2 tumors, ≤2 positive sentinel nodes, undergoing breast-conserving surgery with whole breast irradiation and systemic therapy, SLNB alone without completion ALND is recommended 1, 3

Special Considerations

• The European Society for Medical Oncology recommends that micrometastases after neoadjuvant therapy indicate non-pathological complete response and require different management than treatment-naïve micrometastases 2
• The National Comprehensive Cancer Network recommends that axillary procedures may be considered optional in patients with particularly favorable tumors, elderly patients, or patients with serious comorbid conditions, but these patients have increased risk for ipsilateral lymph node recurrence 4, 9

Key Morbidity Considerations

• SLNB significantly reduces complications compared to ALND, including a 38% risk reduction for lymphedema, decreased shoulder stiffness and pain, and reduced sensory neuropathy 1, 3, 7